GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate
A 24-Week Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined With Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients With Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy With a Statin
Sponsor: AstraZeneca
Terminated
The development program has been terminated
Other terminated trials from AstraZeneca
Other Type 2 Diabetes trials with similar outcome
A PHASE3 clinical study on Type 2 Diabetes, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Mar 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aix-en-Provence, France , Almada, Portugal , Amadora, Portugal , Ambriere LES Vallees, France , Aschaffenburg, Germany , Balatonfüred, Hungary , Bangalore, India , Bay Roberts, Canada , Beckum, Germany , Bergen, Norway and 137 more locations